Zobrazeno 1 - 10
of 1 555
pro vyhledávání: ''
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Serena K. Wolfe, David J. Beebe, Jamie M. Sperger, Jennifer L. Schehr, Erika Heninger, Toni K. Choueri, Xiao X. Wei, Joshua A. Desotelle, Charlotte N. Stahlfeld, Waddah Arafat, Joshua M. Lang, John A. Steinharter, Hamid Emamekhoo, Rana R. McKay, E. Jason Abel, Anupama Singh, Matthew C. Mannino, Tamara S. Rodems, David J. Niles, Rory M. Bade, Benjamin K. Gibbs
Publikováno v:
Molecular Oncology, Vol 15, Iss 9, Pp 2330-2344 (2021)
Molecular Oncology
Molecular Oncology
Although therapeutic options for patients with advanced renal cell carcinoma (RCC) have increased in the past decade, no biomarkers are yet available for patient stratification or evaluation of therapy resistance. Given the dynamic and heterogeneous
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5545-5556 (2021)
Cancer Medicine
Cancer Medicine
Epigenetic regulation is important for cancer tumor metastasis and progression, including lung and liver cancer. However, the mechanism of epigenetic regulation in liver cancer leaves much to be discussed. According to a previous study, p300/CBP‐as
Autor:
Daneng Li, Nicolas Sommer, Wendy Verret, Riad Salem, Riccardo Lencioni, Sairy Hernandez, Beiying Ding
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5437-5447 (2021)
Cancer Medicine
Cancer Medicine
Background IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Explo
Autor:
Yuichi Takahashi, Ryuta Iwamoto, Yurina Mikasa, Mitsuaki Okodo, Ayaka Shirasaki, Ibu Matsuzaki, Fumiyoshi Kojima, Shin-ichi Murata, Fidele Y. Musangile
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5534-5544 (2021)
Cancer Medicine
Cancer Medicine
Background Human papillomavirus (HPV) is a well‐established mucosotropic carcinogen, but its impact on urothelial neoplasm is unclear. We aimed to clarify the clinical and pathological features of HPV‐related urothelial carcinoma (UC). Methods Ti
Autor:
Rajesh Balkrishnan, Aditya Narayan, Lucas E Flausino, Raj P Desai, Roger Chammas, Fabian Camacho
Publikováno v:
Cancer Medicine, Vol 10, Iss 15, Pp 5347-5357 (2021)
Cancer Medicine
Cancer Medicine
Purpose Colorectal cancer (CRC) diagnosis is associated with high mortality in the United States and thus warrants the study of novel treatment approaches. Vascular changes are well observed in cancers and evidence indicates that antihypertensive (AH
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4844-4854 (2021)
Cancer Medicine
Cancer Medicine
Background The purpose of the study was to evaluate the diagnostic value of gamma‐glutamyl transpeptidase to alkaline phosphatase ratio (GAPR) combined with gamma‐glutamyl transpeptidase to aspartate aminotransferase ratio (GAR) and alanine amino
Autor:
Ciara Marie Kelly, Mark A. Dickson, Kaled M. Alektiar, Jung Julie Kang, Havah Bernstein, Kathryn E. Marqueen, Samuel Singer, Brian Neal, Anna Lee, William D. Tap, Chiaojung Jillian Tsai, Nancy Y. Lee
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4221-4227 (2021)
Cancer Medicine
Cancer Medicine
Patients with previously treated, recurrent or metastatic sarcomas who have progressed on multiples lines of systemic therapy may have limited options for local control. We evaluated outcomes of palliative proton therapy with the quad shot regimen to
Autor:
Nirav Patil, Ankit Mangla, Asrar Alahmadi, Nelroy Jones, Richard T. Lee, David L. Bajor, Jill S. Barnholtz-Sloan, Eva Selfridge, Amr Mohamed, Gino Cioffi, Aman Opneja, Tin-Yun Tang, Joel N. Saltzman
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4397-4404 (2021)
Cancer Medicine
Cancer Medicine
Background This study analyzes the pattern of use of single agent anticancer therapy (SAACT) in the treatment and survival of advanced hepatocellular carcinoma (aHCC) before and after sorafenib was FDA approved in 2007. Methods Adult patients diagnos
Autor:
Ting Zheng, Chenyang Jia, Yashuang Zhao, Lin Zhu, Jinming Fu, Ding Zhang, Yupeng Liu, Tian Tian, Haoran Bi, Hao Huang, Hongru Sun
Publikováno v:
Cancer Medicine, Vol 10, Iss 14, Pp 4964-4976 (2021)
Cancer Medicine
Cancer Medicine
X chromosome change has been proved to be associated with carcinogenesis and related to gender differences in cancer risk. If aberrant methylation of genes encoded by X chromosome involve in the risk and prognosis of cancers, including colorectal can